151 related articles for article (PubMed ID: 31721713)
1. In Silico Insights on GD2 : A Potential Target for Pediatric Neuroblastoma.
Limaye A; Sweta J; Madhavi M; Mudgal U; Mukherjee S; Sharma S; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(30):2766-2781. PubMed ID: 31721713
[TBL] [Abstract][Full Text] [Related]
2. Computer-aided Drug Designing for the Identification of High-Affinity Small Molecule Targeting CD20 for the Clinical Treatment of Chronic Lymphocytic Leukemia (CLL).
Sinha K; Majhi M; Thakur G; Patidar K; Sweta J; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(29):2527-2542. PubMed ID: 30526461
[TBL] [Abstract][Full Text] [Related]
3. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
[TBL] [Abstract][Full Text] [Related]
4. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
5. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
6. A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.
Qureshi S; Khandelwal R; Madhavi M; Khurana N; Gupta N; Choudhary SK; Suresh RA; Hazarika L; Srija CD; Sharma K; Hindala MR; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2021; 21(9):790-818. PubMed ID: 33463471
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening of IL-6 Inhibitors for Idiopathic Arthritis.
Shukla P; Khandelwal R; Sharma D; Dhar A; Nayarisseri A; Singh SK
Bioinformation; 2019; 15(2):121-130. PubMed ID: 31435158
[TBL] [Abstract][Full Text] [Related]
8. A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Sharda S; Sarmandal P; Cherukommu S; Dindhoria K; Yadav M; Bandaru S; Sharma A; Sakhi A; Vyas T; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2017; 17(26):2989-2996. PubMed ID: 28828991
[TBL] [Abstract][Full Text] [Related]
9. A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy.
Zhang L; Wang M; Zhu Z; Ding C; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Int J Nanomedicine; 2021; 16():3217-3240. PubMed ID: 34007175
[TBL] [Abstract][Full Text] [Related]
10. The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL).
Rovigatti U
Cancer Lett; 2021 Apr; 503():220-230. PubMed ID: 33271265
[TBL] [Abstract][Full Text] [Related]
11. Structure-based Virtual Screening for the Identification of High-affinity Small Molecule Towards STAT3 for the Clinical Treatment of Osteosarcoma.
Khandelwal R; Chauhan APS; Bilawat S; Gandhe A; Hussain T; Hood EA; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(29):2511-2526. PubMed ID: 30430945
[TBL] [Abstract][Full Text] [Related]
12. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
[TBL] [Abstract][Full Text] [Related]
13. Identification of High-affinity Small Molecules Targeting Gamma Secretase for the Treatment of Alzheimer's Disease.
Ali MA; Vuree S; Goud H; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1173-1187. PubMed ID: 31244427
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer.
Mukherjee S; Abdalla M; Yadav M; Madhavi M; Bhrdwaj A; Khandelwal R; Prajapati L; Panicker A; Chaudhary A; Albrakati A; Hussain T; Nayarisseri A; Singh SK
J Mol Model; 2022 Mar; 28(4):100. PubMed ID: 35325303
[TBL] [Abstract][Full Text] [Related]
15. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
[TBL] [Abstract][Full Text] [Related]
16. In silico Insights on IL-6: A Potential Target for Multicentric Castleman Disease.
Aher A; Udhwani T; Khandelwal R; Limaye A; Hussain T; Nayarisseri A; Singh SK
Curr Comput Aided Drug Des; 2020; 16(5):641-653. PubMed ID: 31475901
[TBL] [Abstract][Full Text] [Related]
17. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
19. Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.
Müller J; Reichel R; Vogt S; Müller SP; Sauerwein W; Brandau W; Eggert A; Schramm A
PLoS One; 2016; 11(10):e0163648. PubMed ID: 27716771
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.
Sabbih GO; Danquah MK
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
